Not yet reviewed
Alina Denis Jarjour, JD (Business Attorney & Corporate Compliance Advisor):
Represents the interests of individuals, companies and organizations with an emphasis on those involved in the highly-regulated healthcare, life sciences, consumer products, media, telecommunications and technology sectors.
Manages or provides support to corporate legal and compliance departments, on an interim basis during periods of transition or on an ongoing basis day-to-day.
Negotiates commercial transactions.
Creates, Expands and Maintains corporate compliance programs.
Advises individuals, companies and organizations (including boards) on legal, risk reduction, governance, HR, commercial and operational issues.
Speaks on / Teaches all of the above.
Languages spoken: Spanish
Endorsements from fellow lawyers are an important consideration for many when selecting the right attorney. Be the first to endorse your colleague!
Are you an attorney? Endorse this lawyer
|FL||Member in Good Standing||1991||10/02/2016|
|Adjunct Professor||Florida International University||2015 - Present|
|Axiom Attorney||Axiom Global Inc.||2015 - Present|
|Principal and Chief Counsel||Jarjour | Legal||2011 - Present|
|Corporate Compliance & Strategy Advisor||Telecommunications Management Group, Inc.||2005 - Present|
|General Counsel, Chief Compliance Officer & Corporate Secretary||EKR Therapeutics||2010 - 2011|
|Deputy General Counsel & Chief Compliance Officer||Medarex||2006 - 2010|
|Association name||Position name||Duration|
|BioNJ (Biotechnology Industry Organization)||Legal Advisory Member & Past Co-Chair (2009-13)||N/A|
|Florida Bar||Attorney Member||N/A|
|The New Jersey State Bar Association||Attorney Member||N/A|
|HandsOn Miami||Project Leader||N/A|
|Florida International University||Member, President's Council||N/A|
|Family Service Association of Bucks County, Pennsylvania||Member, Board of Directors (2010-13)||N/A|
|Florida Bar, Health Law Section||Coming Soon: FDA's Final Guidance on the Use of Social Media to Advertise Drugs and Biologics||2014|
|Florida Bar, Health Law Section||Generic Drug Labeling Change Proposed by FDA is Significant and Will Likely Negate Preemption of State Failure-to-Warn Claims in Generic Drug Cases||2013|
|Blog||Jarjour | Legal||2012|
|Boston University||Mini-MBA Program||Not Applicable||N/A|
|University of Pennsylvania Law School||Law||JD - Juris Doctor||N/A|
|Healthcare and Financial Services Compliance Boot Camp||A Case in Point: Healthcare and Special Areas of Concern||2015|
|10th Annual Pharmaceutical Compliance Congress||Role of Compliance within Promotional Review Committee Structure & Processes||2013|
|Women2Women2Girls Tele-Summit||Reinventing for Relevance||2011|
|Chief Legal Officer Leadership Forum: Spotlight on Pharmaceuticals & Biotechnology||Joint Ventures, Alliances & Collaborations: Legal Issues & Considerations||2011|
|Life Sciences Forum & Continuing Education Program (ACC: New Jersey Chapter)||Critical Compliance Issues in Clinical Trials & Medical Activities||2010|
|BioNJ Legal Forum||Role of Legal, Compliance & Regulatory in Managing Risks Outside the US||2010|
|Health Care Compliance Association (HCCA) Research Conference||Effectively Preparing for & Responding to an FDA Audit||2009|